Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


PRINCIPAL STOCKHOLDERS

        The following table sets forth information regarding the number of shares of common stock beneficially owned on July 31, 2014, and immediately following consummation of this offering, by:

    each person who is known by us to beneficially own 5% or more of our common stock;
    each of our named executive officers and directors; and
    all of our current executive officers and directors as a group.

        We have determined beneficial ownership in accordance with SEC rules. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.

        Applicable percentage ownership is based on 232,526,816 shares of common stock outstanding at July 31, 2014 and gives effect to the automatic preferred stock conversion. For purposes of the column entitled "Shares Beneficially Owned After Offering," we have assumed that                shares of common stock will be issued and outstanding upon completion of this offering. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options held by that person or entity that are currently exercisable or exercisable within 60 days of July 31, 2014. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

        Except as otherwise set forth below, the address of each beneficial owner is c/o Vitae Pharmaceuticals, Inc. 502 West Office Center Drive, Fort Washington, Pennsylvania 19034.

 
  Shares Beneficially
Owned Prior to Offering
  Shares Beneficially
Owned After Offering
 
Name of Beneficial Owner
  Number   Percentage   Number   Percentage  

5% or Greater Stockholders

                         

Prospect Venture Partners

    54,270,053 (1)   23.3 %            

New Enterprise Associates

    41,393,800 (2)   17.8 %            

Venrock Associates

    36,383,387 (3)   15.6 %            

Atlas Venture

    26,146,808 (4)   11.2 %            

Boehringer Ingelheim International GmbH

    25,000,000 (5)   10.8 %            

Allergan, Inc. 

    13,107,978 (6)   5.6 %            

Executive Officers and Directors

   
 
   
 
   
 
   
 
 

Jeffrey S. Hatfield

    4,375,406 (7)   1.8 %            

Arthur Fratamico, R.Ph. 

                     

Tina Fiumenero

    2,680,039 (8)   1.1 %            

Richard Gregg, M.D. 

    4,320,780 (9)   1.8 %            

Richard Morris

                     

Peter Barrett, Ph.D. 

    26,146,808 (10)   11.2 %            

Robert V. Gunderson, Jr. 

    951,288 (11)   *              

Donald Hayden, Jr. 

    1,991,180 (12)   *              

Charles W. Newhall, III

    (13)   *              

Bryan Roberts, Ph.D. 

    36,383,387 (14)   15.6 %            

All current executive officers and directors as a group (9 persons)

    74,168,849 (15)   30.5 %            

*
Represents beneficial ownership of less than 1% of the outstanding shares of our common stock.

(1)
Includes 43,716,588 shares held by Prospect Venture Partners II, L.P., 9,103,465 shares held by Prospect Venture Partners, L.P., 725,000 shares held by Prospect Venture Partners, L.P., as Nominee

143